AgelessRx rapamycin research programme
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youRejuvAccess combines AI, personal research, health improvement and access help so you can act on what may help now—and be ready when something new opens.
Availability is only the start. We check what it may do, who offers it, what it costs and whether the evidence makes it worth considering.
If the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youThis could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
See what this could mean for youThis could keep someone alive and healthier when an organ is failing by repairing it, supporting it or replacing it.
See what this could mean for youUse AI to work through your goals, habits, supplements, risks and the projects you are following. Move from a general question to a useful next action.
“I want to lower my biggest risks now, but I also want to follow treatments that could matter in the next five years. Where do I begin?”
Projects, studies, medicines, services and providers are followed for developments that may matter.
We compare the claim with the evidence, risk, cost and real stage of development.
You hear when recruitment opens, results arrive, access changes or a better route appears.
We investigate the route, prepare questions and help you approach the relevant organisation or expert.
Reducing avoidable risk can give you more healthy time and a stronger position from which to benefit from future advances.
Some of the most important routes are still early. We follow them because the opportunity may be greatest before they become general news.
If the project succeeds, it could add another practical route to prevent, delay or repair age-related decline.
See what this could mean for youIf the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youIf the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youIf the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youIf the effect in people is large enough, this could become a medicine used to slow one or more processes that drive age-related decline.
See what this could mean for youIf it works, it could remove or quiet damaged cells that build up with age and disturb the healthy cells around them.
See what this could mean for youFollow your own priorities, ask questions, receive relevant updates and use personal research and access support when you need it.